Currently, there are 209.44M common shares owned by the public and among those 177.47M shares have been available to trade.
The company’s stock has a 5-day price change of 9.60% and 24.55% over the past three months. HIMS shares are trading 15.18% year to date (YTD), with the 12-month market performance up to 231.15% higher. It has a 12-month low price of $8.14 and touched a high of $35.02 over the same period. HIMS has an average intraday trading volume of 15.88 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.20%, 1.84%, and 37.79% respectively.
Institutional ownership of Hims & Hers Health Inc (NYSE: HIMS) shares accounts for 56.09% of the company’s 209.44M shares outstanding.
It has a market capitalization of $6.08B and a beta (3y monthly) value of 1.30. The stock’s trailing 12-month PE ratio is 64.42, while the earnings-per-share (ttm) stands at $0.43. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.98% over the week and 7.99% over the month.
Analysts forecast that Hims & Hers Health Inc (HIMS) will achieve an EPS of 0.21 for the current quarter, 0.22 for the next quarter and 0.98 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.16 while analysts give the company a high EPS estimate of 0.16. Comparatively, EPS for the current quarter was 0.05 a year ago. Earnings per share for the fiscal year are expected to increase by 592.48%, and -3.75% over the next financial year.
Looking at the support for the HIMS, a number of firms have released research notes about the stock. Citigroup stated their Sell rating for the stock in a research note on January 10, 2025, with the firm’s price target at $24-$25. BTIG Research coverage for the Hims & Hers Health Inc (HIMS) stock in a research note released on January 07, 2025 offered a Buy rating with a price target of $35. Needham on their part issued Buy rating on August 22, 2024.
